JILIN, China, June 9 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. (OTC:GBLP.OB) (BULLETIN BOARD: GBLP.OB) a company that develops, manufactures and markets proprietary drugs and nutritional supplements that are based on modernized Chinese medicine and bio-pharmacy, today announced that it had been granted an invention patent on its Jutai soft capsules product. An invention patent is China's highest and most prestigious grade of patent protection, and is given to technology that is considered genuinely innovative. The State Intellectual Property of the People's Republic of China granted patent protection for the Jutai soft capsule as "an immune modulating and anti-fatigue product." This patent also protects the methods of product preparation, utility as well as methods of quality control. The Chinese patent number is ZL03119221.1. Jutai soft capsules consist of active ingredients of American Ginseng and Echinacea, and the product was developed in accordance with the theory of Traditional Chinese Medicine. Pharmacology studies showed that Jutai enhanced immune activity and had an anti-fatigue function in animal models. Since the product's launch in China in 2003, no side effects have been reported. Dr. Xiaobo Sun, CEO of Global Pharmatech, is one of the most distinguished scientists in the field of botanical medicines. He stated, "We are extremely pleased to have been awarded a patent on this product. People are overworked and multi-tasking these days, and they are looking for ways to boost their energy. We developed Jutai soft capsule as a dietary supplement to meet precisely this major need in the market. And with the protection of this patent for the next 20 years, we are in a better position to ramp up future sales." About Global Pharmatech Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine using modern facilities and advanced R&D technologies. The company offers a full range of start-to-finish biotech services, from research and testing to manufacture and sale of liquid and solid dose products. The Company employs unique proprietary extraction methods and also licenses patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution centers in China, Malaysia, Singapore and Indonesia. For more information, please visit Global Pharmatech.com Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop and commercialize products, competitive products in our key markets, changes in consumer demand for our products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. For more information, please contact: Joseph Levinson Chief Financial Officer Global Pharmatech, Inc. Tel: +1-905-787-8225 Email: Or Zhuojun Li Investor Relations Global Pharmatech, Inc. Tel: +1-905-787-8225 Email: DATASOURCE: Global Pharmatech, Inc. CONTACT: Joseph Levinson, Chief Financial Officer, +1-905-787-8225, , or Zhuojun Li, Investor Relations, +1-905-787-8225, , both of Global Pharmatech Inc. Web site: http://pharmatech.com/

Copyright